Leslie Randall, MD
Gynecologic Oncology · Fairfax, VANPI 1821054602
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 15.9%. Reporting peaked in 2022 at $97,238 and has fallen 66.1% since, to $32,954 in 2025. Among gynecologic oncology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 330 payments — averaging $1035.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab U.S., Inc.$54K
- Seagen Inc.$49K
- Tesaro, Inc.$45K
- GSK$42K
- AstraZeneca$41K
- Merck$29K
- plus $80K from 23 others
Across 147 payments — averaging $11,963 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- Pfizer$194K
- AstraZeneca$157K
- Seagen Inc.$93K
- Amgen$53K
- GSK$47K
- plus $47K from 5 others
What the payments were for
- Consulting fees$155,76546%
- Speaking & faculty fees$152,83645%
- Travel & lodging$21,7456%
- Food & beverage$11,2443%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab U.S., Inc. | 22 | $54,336 |
| Seagen Inc. | 44 | $49,122 |
| Tesaro, Inc. | 43 | $45,485 |
| GSK | 24 | $42,308 |
| AstraZeneca | 48 | $40,810 |
| Merck | 35 | $29,089 |
| Pfizer | 21 | $19,169 |
| Eisai Inc. | 10 | $11,731 |
| AbbVie | 16 | $9,699 |
| Daiichi Sankyo Inc. | 7 | $7,218 |
| Regeneron | 6 | $4,401 |
| Immunogen, Inc. | 5 | $3,522 |
| EMD Serono, Inc. | 1 | $3,450 |
| Clovis Oncology, Inc. | 8 | $3,221 |
| Myriad Genetic Laboratories, Inc. | 3 | $3,097 |
| Novartis | 2 | $2,508 |
| Gilead | 5 | $2,499 |
| Novocure GmbH | 1 | $2,400 |
| Aadi Bioscience, Inc. | 2 | $2,250 |
| Novocure Inc. | 5 | $2,240 |
| Astrazeneca UK Limited | 3 | $1,406 |
| Corcept Therapeutics | 7 | $926 |
| Intuitive Surgical | 3 | $249 |
| Genentech USA, Inc. | 2 | $212 |
| Johnson & Johnson | 1 | $130 |
| Tempus AI, Inc | 2 | $54 |
| Davol Inc. | 2 | $47 |
| Caris MPI, Inc. | 1 | $36 |
| Exelixis Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$341,633 in reported general payments places this provider in the 95th percentile of 47 gynecologic oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 14 | $201 |
| Letrozole | 18 | $176 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Fairfax
- John ElkasFairfax$7K
- Jessica LeeFairfax$6K
- Kathryn MillerFairfax$4K
- Sushmita GordhandasFairfax$4K
- Marina ArutyunyanFairfax$689
- Cecelia BoardmanRichmond$577K
- Chad HamiltonAnnandale$242K
- Samantha BatmanCharlottesville$76K
- Linda DuskaCharlottesville$72K
- Marilyn HuangCharlottesville$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.